The Mag 7: The Big Tech Exodus

The trade that defined a generation just cracked. Here's where the money is going.  ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌ ‌

March 27, 2026 The Big Tech Exodus The Mag 7 correction isn't a dip. It's a regime change. What You Need to Know The Magnificent 7 are collectively down 10% from their 2026 highs — the first meaningful group-wide correction this year. Microsoft froze hiring across Azure cloud and North American sales, citing the need to cut costs and boost margins amid $37.5 billion in quarterly AI capex. Nvidia's valuation has reset sharply; MSFT shares have fallen roughly 24% year-to-date, the worst start to a year on record for the stock. Brent crude hit $107.81 per barrel on March 27, up roughly $34 from a year ago, driven by effective closure of the Strait of Hormuz. Capital is rotating into Hard Science (biotech names like KOD and RCKT) and Energy, the only S&P 500 sector in positive territory this month. RCKT surged 11% premarket after FDA approved its gene therapy Kresladi — its first commercial product — and the stock is up 34% year-to-date. KOD reported positive Phase 3 topline data for Zenkuda on March 26, with 62.5% of patients achieving the primary endpoint vs. 3.3% for sham. Hey there, bargain hunter. For years, the trade was simple. Load up on the seven biggest tech names in America, go home, and collect the outperformance. It worked beautifully — until 2026 decided the market needed a new script. The Magnificent 7 are collectively down 10% from their highs. That's not a garden-variety pullback. That's the sound of a consensus trade breaking apart at the seams. Sponsored Mag 7's relentless assault on Nvidia's future Nvidia's biggest customers are now buying and selling chips to each other. That means, the virtual monopoly that fueled NVDA's $4 trillion market cap is OVER. If you currently own NVDA, here's a better alternative. Their competition is scarce, which puts them in a hugely advantageous spot. This supplier's stock has outperformed Nvidia's by 50X since July. Click to get the full details on this urgent "Nvidia alternative" right here. What the Market Believed The thesis was seductive and not entirely wrong: these seven companies were the infrastructure layer of the AI revolution. Whoever controls the compute, the cloud, and the ad stack wins the decade. So investors priced them accordingly — the Magnificent 7 index trading at nearly 29 times forward earnings earlier this year, a 26% premium to the broader S&P 500. The assumption baked into every price: AI spending would translate into margin expansion, and soon. The market was not buying hype. It was buying a timeline. What Actually Changed The timeline got complicated. Microsoft — still one of the most closely watched AI proxy trades in the market — just froze hiring across its Azure cloud and North American sales divisions. Executives instructed managers to halt the hiring of any new candidates who did not already have a job offer, citing the need to cut costs and boost margins. This is not a seasonal quirk. This is a company sitting on $37.5 billion in quarterly AI infrastructure capex, watching the gap between revenue growth and gross margin performance refuse to close. The internal message from Azure leadership was unambiguous: until margins improve, no new hires. Meanwhile, OpenAI accounts for roughly 45% of Azure's revenue backlog — meaning Microsoft's growth engine is tethered to a single partnership that demands constant GPU spend. That is not the profile of a business ready to compound its way to 34x earnings. MSFT shares are down roughly 24% year-to-date. The worst start to a year on record. Nvidia reset on valuation concerns, though its fundamentals remain operationally impressive — data center revenue surged 75% year-over-year to $62 billion in its most recent quarter. The correction here is about multiple compression, not business deterioration. Meta carries its own legal overhang, and profit growth across the group is expected to slow to roughly 18% in 2026 — barely better than the other 493 companies in the S&P 500. That's where things get interesting. The Real Insight The market isn't abandoning Big Tech because it stopped believing in AI. It's abandoning the idea that all seven names deserve the same premium for the same reason at the same time. Investors are no longer buying the group on blind faith — they're running an ROI audit. And several of these companies are failing it. The era of the easy trade — buy an index of the seven largest tech stocks and expect outperformance — is over. What replaces it is more interesting, and more selective. Sponsored Buy Now Before it Potentially Trades Med-X is moving toward a possible Nasdaq listing (ticker: MXRX) - and once that happens, the early window closes. Before Wall Street prices it in, Med-X has already generated $6.4M in sales, placed its Nature-Cide products on Amazon.com, Walmart.com, and Kroger.com, and begun expanding into 41+ global markets. Independent lab tests show Nature-Cide outperforming chemical pesticides - right as regulators and consumers force the $17B pest control industry to go natural. This is the gap before the bell. Review the Med-X opportunity now - before Nasdaq plans unfold. Disclosures: This is a paid advertisement for Med-X's Regulation A+ Offering. Please read the offering circular at invest.medx-rx.com. Where the Money Is Going Two sectors are absorbing the rotation: Hard Science biotech and Energy. On the biotech side, the setup is structural, not speculative. Over $200 billion in annual pharmaceutical revenue is at risk from patent expirations through 2028. Major pharma companies are sitting on more than $1.5 trillion in acquisition firepower. Morgan Stanley has already flagged continued outperformance for US small-to-mid cap biotech, noting that commercial-stage companies are shifting from consuming capital to producing it. Kodiak Sciences (KOD) just reported positive Phase 3 topline data for Zenkuda on March 26, with 62.5% of patients hitting the primary endpoint versus 3.3% for sham — with an 85% risk reduction in sight-threatening complications. The company says it has a BLA-ready profile and intends to accelerate its submission timeline. Rocket Pharmaceuticals (RCKT) moved 11% in premarket after the FDA approved its gene therapy Kresladi — the company's first commercial product. The stock is up 34% year-to-date. The commercial milestone matters less for near-term revenue (the target disease treats fewer than 10 patients per year) and more because it de-risks the entire gene therapy platform and manufacturing network for future approvals. On the energy side, the catalyst is blunter. Brent crude hit $107.81 per barrel on March 27, roughly $34 above where it traded a year ago. The Strait of Hormuz is effectively closed following escalating military conflict. Global oil supply is projected to fall by 8 million barrels per day in March alone, according to IEA data. Energy is the only S&P 500 sector in positive territory this month, gaining more than 9% in March. ConocoPhillips jumped 3.2% on March 26 alone. Valero's refining margins hit $18.65 per barrel, with the stock up 26% in March. This isn't a momentum trade. It's a supply shock with no clear resolution on the horizon. What I'm Watching Azure margin trajectory: The gap between Azure revenue growth and gross margin performance is the tell. If it narrows, the hiring freeze lifts and the MSFT thesis resets. If it widens, the stock has further to fall. KOD BLA submission timing: Zenkuda's Phase 3 data is strong. Watch for BLA filing confirmation and FDA response timeline, which would be the primary near-term catalyst. RCKT pipeline beyond Kresladi: The Danon disease Phase 2 restart in H1 2026 is the real prize. Kresladi's approval clears the regulatory runway; Danon is the revenue story. Strait of Hormuz resolution: Any diplomatic breakthrough de-prices the energy trade fast. The IEA forecasts Brent falling below $80 in Q3 if disruptions ease. Watch weekly inventory reports and FOMC language for leading signals. Mag 7 Q1 earnings (April-May): Growth and valuation are the two dimensions where the group is most differentiated. The upcoming earnings cycle is the next major reset event — for better or worse. Bottom Line The Mag 7 correction is not a buying opportunity dressed up as a crisis. It's a repricing event — the market asking a question these companies have avoided answering for two years: where are the returns on all that AI spend? Until Microsoft shows margin improvement, until Nvidia's premium is justified by enterprise adoption at scale, and until Meta navigates its legal exposure, the headwind is structural, not cyclical. The money that's leaving isn't sitting in cash. It's finding its way into companies with hard catalysts — FDA approvals, Phase 3 readouts, and oil fields that don't care about your AI roadmap. The trade that defined the last three years just handed you a map to the next one. The question is whether you're reading it. This editorial is for informational purposes only and does not constitute investment advice, a solicitation, or a recommendation to buy or sell any security. All investing involves risk, including the possible loss of principal. Past performance is not indicative of future results. Always conduct your own due diligence before making any investment decision. IMPORTANT NOTICE AND DISCLAIMER Investing Media Solutions, LLC ("IMS"), the owner of this website (the "Website"), cannot guarantee the accuracy or completeness of the information contained in any article, email, newsletter, or other publication posted on or viewed in connection with this website (the "Publications"). The author or authors of those Publications are solely responsible for their contents. IMS has not done any research or due diligence into the markets, industries, or companies which may appear or be mentioned in the Publications. IMS will NOT be liable for any loss or damage caused by a reader's reliance on information posted on the Website or contained in the Publications. FOR EDUCATIONAL AND INFORMATIONAL PURPOSES ONLY; NOT INVESTMENT ADVICE. This Website and the Publications are for educational and informational purposes only. This Website and the Publications do not purport to be a complete analysis of any company's financial position. This Website, the Publications or any statements made in the Publications are not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular individual. This Website or the statements made in the Publications should NOT be relied upon for purposes of transacting in any securities posted on the Website or mentioned in the Publications, nor should they be construed as a personalized recommendation to you to buy, sell, or hold any position in any security posted on this Website or mentioned in any Publications. SUBSTANTIAL RISK IN INVESTMENT. Any individual who chooses to invest in any securities including those mentioned in the Publications should do so with caution. Investing or transacting in securities involves substantial risk; you may lose some, all, or possibly more than your original investment. Readers bear responsibility for their own investment research and decisions and should review all investment decisions with a licensed or registered investment professional. NOT AN INVESTMENT ADVISOR OR REGISTERED BROKER Neither IMS nor any of its respective owners or employees are registered or licensed as a securities broker-dealer, broker, an investment advisor, or an investment advisor representative with the U.S. Securities and Exchange Commission (SEC), any state securities regulatory authority, or any self-regulatory organization. To more fully understand our Website, please review our full disclaimer located at: https://thecheapinvestor.com/disclaimer/ At The Cheap Investor, it's our mission to create and provide a community that helps you invest and understand stocks. When TheCheapInvestor was established, we wanted to make the community an inclusive place where investors can come to get ahead! Not just help them with daily stock picks. The Cheap Investor are provided to you for information only and should not be considered as a stock or investment advisor. The Cheap Investor may make available certain information related to trading strategies and stock prices for educational and information purposes only; any information made available should not be construed as an endorsement, recommendation, or sponsorship of any company or security. By visiting this site or using the training materials, you acknowledge and agree that any reliance upon the content or data available through The Cheap Investor is at your own sole risk. You are strongly advised to use your own judgment, research, and consult a professional advisor. Over the years, and with thousands of followers that use our stock picks daily, we promise to always aim to get better at what we do every single day! In addition, our primary focus is on our communication with you. It's really important to us that every time you come to us, you end up leaving with the help you came for to take your investment portfolio to new levels. We particularly appreciate when our following provides feedback via testimonials, reviews, and comments left on our site or social media accounts. Because with that feedback, we can use it to make your next visit to our site even better than the last! Since we put so much effort into the relationship with you, we hope that any investment in us is exactly the way you hoped it would be. Because by choosing to go with https://TheCheapInvestor.com/, it's our promise that we provide a community you will come back to over and over again. Now, as much as we care about making investors more successful, we also care about your privacy. TheCheapInvestor is owned and operated by TheCheapInvestor website. We're committed to the right to your privacy and strive to provide a safe and secure user experience. Our Privacy Policy explains how we collect, store and use personal information, provided by you on our website. What Information Do We Collect? When you visit our Web site you may provide us with two types of information: personal information you knowingly choose to disclose that is collected on an individual basis and Web site use information collected on an aggregate basis as you and others browse our Web site. For example, you may need to provide the following information: • Name • Website URL information • Email address • Home and business phone number In addition to providing the foregoing information, if you choose to correspond further with us through email, we may retain the content of your email messages together with your email address and our responses. We provide the same protections for these electronic communications that we employ in the maintenance of information received by mail and telephone. It also explains important information that ensures we won't abuse the information that you provide to us in good faith. By accessing and using our website, you can trust that what you want to be kept private, will be kept private. If at any time, you would like to read our Privacy Policy and get a better understanding of your rights and liabilities under the law. Feel free to visit our site, find the privacy policy in the footer and read it. If there is something you are concerned about or wish to get more clarity on, please let us know by contacting us at support@thecheapinvestor.com. The Privacy Policy also informs you of how to notify us to stop using your personal information. If you wish to view our official policies, please visit our website https://TheCheapInvestor.com/ At The Cheap Investor, we are strongly committed to protecting your privacy and providing a safe & high-quality online experience for all of our visitors. We understand that you care about how the information you provide to us is used and shared. We have developed a Privacy Policy to inform you of our policies regarding the collection, use, and disclosure of information we receive from users of our website. The Cheap Investor operates the Website. Our Privacy Policy, along with our Term & Conditions, governs your use of this site. By using https://TheCheapInvestor/, or by accepting the Terms of Use (via opt-in, checkbox, pop-up, or clicking an email link confirming the same), you agree to be bound by our Terms & Conditions and our Privacy Policy. If you have provided personal, billing, or other voluntarily provided information, you may access, review, and make changes to it via instructions found on the Website or by emailing us at support@thecheapinvestor.com. To manage your receipt of marketing and non-transactional communications, you may unsubscribe by clicking the "unsubscribe" link located on the bottom of any marketing email. Emails related to the purchase or delivery of orders are provided automatically – Customers are not able to opt out of transactional emails. We will try to accommodate any requests related to the management of Personal Information in a timely manner. However, it is not always possible to completely remove or modify information in our databases (for example, if we have a legal obligation to keep it for certain timeframes, for example). If you have any questions, simply reply to this email or visit our website to view our official policies. Update your email preferences or unsubscribe here © 2026 The Cheap Investor 203 N La Salle Suite 2100 Chicago , Illinois 60601, United States Powered by beehiiv Terms of Service